Walleye Capital’s BioAtla BCAB Stock Holding History

Walleye Capital’s Portfolio BCAB Stock Details BCAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-3,407	Closed	-$852K	–	2361
2022 Q1	$852K	Buy	+3,407	New	+$1.43M	0.02%	714

Other funds holding BCAB

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Walleye Capital's BCAB Position: Q2 2022 in Review

Walleye Capital sold out of BioAtla (BCAB) in Q2 2022, closing a stake of 3,407 shares — an estimated $852K sold.

Walleye Capital first reported a position in BCAB in Q1 2022 and held it in 1 quarter. The position peaked at $852K in Q1 2022. 76 funds tracked by Wall St. Rank hold BCAB as of Q2 2022.

Walleye Capital reported no remaining BioAtla position as of Q2 2022 after selling out during the quarter.
Walleye Capital sold 3,407 BioAtla shares in Q2 2022, an estimated $852K.
Walleye Capital first reported a position in BioAtla in Q1 2022 and held it in 1 quarter.
Walleye Capital's BioAtla position peaked at $852K in Q1 2022.
76 funds tracked by Wall St. Rank held BioAtla as of Q2 2022.

Based on Walleye Capital's 13F filing for Q2 2022, filed 8 Aug 2022.